Merck & Co., Inc. MRK
148.78
0.80
0.54%
as of 25 Sep
- Market cap
- $365.4B
- P/E
- 119×
Follow MRK
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Merck & Co., Inc. (MRK) Net margin
Merck & Co., Inc.'s net margin over the twelve months to 30 June 2026 was 4.77%, down 23.3 percentage points from fiscal 2025 (28.1%). Over the past ten years it has ranged from 0.61% (fiscal 2023) to 28.1% (fiscal 2025) — the current reading is the highest in ten years. That is below the Drug Manufacturers General industry median of 8.27% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 28.1% | 1.40 |
| FY2024 | 26.7% | 26.07 |
| FY2023 | 0.61% | (23.88) |
| FY2022 | 24.5% | (2.30) |
| FY2021 | 26.8% | 9.77 |
| FY2020 | 17.0% | (8.14) |
| FY2019 | 25.2% | 10.45 |
| FY2018 | 14.7% | 8.74 |
| FY2017 | 5.97% | (3.88) |
| FY2016 | 9.85% | (1.40) |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | −8.04% | 17.99 |
| Mar 2026 | −26.0% | (44.10) |
| Dec 2025 | 18.1% | (15.42) |
| Sep 2025 | 33.5% | 5.48 |
| 42 more quarters | Free account |
Against its own ten years
Low 0.61%
High 28.1%
Ten-year median
17.0%
Current reading's percentile
100
Net margin against peers
| Company | Net margin |
|---|---|
| NVO Novo Nordisk A/S compare | 35.5% |
| AMGN Amgen Inc. compare | 23.0% |
| NVS Novartis AG compare | 22.5% |
| JNJ Johnson & Johnson compare | 21.5% |
| AZN AstraZeneca PLC compare | 17.0% |
| ABBV AbbVie Inc. compare | 9.74% |
| PFE Pfizer Inc. compare | 6.80% |
| MRK Merck & Co., Inc. | 4.77% |
| GILD Gilead Sciences, Inc. compare | −10.6% |
| Drug Manufacturers General industry median | 8.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on MRK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement